Dr. Mehling is the founder and chief medical officer of Mehling Orthopedics and BHI Therapeutic Sciences (BHITS). He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He conducts research in regenerative medicine and stem cell science. A study involving human umbilical cord blood cells has been registered on ClinicalTrials.gov (Identifier: NCT03735277). There is no IND in effect, and registration on ClinicalTrials.gov does not indicate FDA approval or endorsement.
Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in Chemistry (which he is currently completing at Seton Hall University). Dr. Mehling is also a member of the prestigious International Society for Stem Cell Research (ISSCR).
Dongecheng Wu, MD, Ph.D., manager and chief scientist of Wuhan Hamilton Biotechnology Co., Ltd. and his team will begin a study entitled “Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis.” Dr. Wu is also the chairman of the Scientific Advisory Board of BHI Therapeutic Sciences.
Dr. Wu is a Professor at Wuhan University School of Basic Medical Science and a Chu Tian Scholar.
BHI Therapeutic Sciences supports investigational research and education in stem cell and regenerative medicine using cord blood cells. A study involving human umbilical cord blood cells has been registered on ClinicalTrials.gov (Identifier: NCT03735277). There is no IND in effect, and registration on ClinicalTrials.gov does not indicate FDA approval or endorsement.
For more information, please visit www.bhisciences.com.
